

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICATION FOR UNITED STATES PATENT  
for  
IMPROVED PROTEINACEOUS ANIMAL CHEW WITH  
DENTALLY THERAPEUTIC CATION

Inventor: **R. Eric Montgomery**  
29 Fairview Road  
Monterey, MA 01245

Attorney Docket: 1910/174

Attorneys:  
**BROMBERG & SUNSTEIN LLP**  
125 Summer Street  
Boston, MA 02110  
(617) 443-9292

659160-95136E60

**IMPROVED PROTEINACEOUS ANIMAL CHEW WITH  
DENTALLY THERAPEUTIC CATION**

Related U.S. Application(s)

5  
This application is a continuation of U.S. application Serial No. 08/689,475,  
filed August 15, 1996 that claims priority from U.S. provisional application Serial  
No. 60/002,345, filed August 15, 1995. Both of these related applications are hereby  
10 incorporated herein by reference.

Technical Field

The invention is directed to methods and compositions for delivery of  
therapeutic agents to an animal by oral administration.

Background art

15 It is known that the dental health of dogs or other domestic animals is often  
deficient owing to the impossibility of achieving an effective brushing of their teeth  
with suitable dental products in a way comparable to that in humans.

20 A number of therapeutic proteinaceous animal chews have been described in  
the prior art to address this problem. The therapeutic effect from these prior art  
compositions or devices comes primarily from the physical act of chewing an object  
to provide an abrasive effect on the teeth prior to swallowing the compositions. The  
act of regularly chewing an object (such as rawhide) sufficiently rigid to allow for an  
25 oral residence time of greater than thirty seconds or so has been shown to result in  
reduced tartar accumulation compared to a quickly consumable object, such as a  
biscuit (Lags, et al J. Am. Veterinary Medical Ass, 197, pp 213-219 (1990)).

Simone et al. US patent No 5,296,209, reported on an attempt to clean an animal's teeth through providing a foodstuff with a texture that allows for the animals tooth, during the act of chewing, to penetrate relatively deep into the food particle before it breaks apart into smaller particles. By doing so, the tooth surface is mechanically abraded by the food particle for a longer period of time than would be possible with a hard, readily breakable food particle. The disadvantage to this approach to companion animal dental hygiene is that only physical accumulation such as tartar, and perhaps some plaque structure, are removed. There is little offered in the way of a truly therapeutic or preventative effect.

These animal chews may in certain instances contain therapeutic compositions in addition to the chew itself. Compositions that have been incorporated into the animal chew may be identified as belonging to one of two categories. The first category is that of enzymatic compositions exemplified by Montgomery US patent 5,310,541. Enzymatic compositions have been found to have limited antimicrobial effect. The second category is that of non-enzymatic compositions associated with the animal chews.

For example, Stacey , US Patent No 5,296,217, described the use of a hexametaphosphate salt added to a consumable animal treat or foodstuff in order to prevent tartar accumulation in domestic animals. Not only is the residence time of the salt too short to have a significant therapeutic effect in the oral cavity of the animal, but furthermore, the hexametaphosphate is not antimicrobial. In Spanier et al., US patent Nos 5, 114,704 and 5,011,679, a rawhide carrier coated with an inorganic pyrophosphate compound was described for purposes of preventing tartar accumulation in dogs. Pyrophosphate is a calcium chelator that limits the accumulation of tartar and reduces the tartar build-up that has occurred. However, this composition lacks antimicrobial properties.

There are a number of cationic antimicrobial agents that have been utilized in

toothpastes for human dental care. These agents strongly associate with protein and are not readily released from proteinaceous substrates.

There is an unmet need for an animal chew that has effective antimicrobial properties in the oral cavity of an animal.

5

### Summary of the Invention

The invention satisfies the above need. A novel animal oral care composition is provided that includes a carrier having a negatively-charged surface and an  
10 effective dose of a therapeutic composition for achieving antimicrobial activity in the oral cavity of the animal, wherein the therapeutic composition contains at least a cationic antimicrobial substance and is in a saliva soluble form positioned close to or at the surface of the proteinaceous carrier. A method is further provided for providing dental health in an animal, including obtaining an animal oral care  
15 composition as described above and administering the composition to the animal in a form that will be voluntarily chewed by the animal.

### Detailed Description

The invention provides a composition and method directed to the dental  
20 health and well-being of animals and includes the following features. Firstly, the composition is safe for consumption, much as a foodstuff or animal feed would be; secondly, human intervention is not required in the companion animal oral care process; thirdly, in order to satisfy the self-administration rule, the composition in association with a carrier, is sufficiently palatable for the animal to maintain its  
25 interest in consuming the material; fourthly, the residence time of the composition and the carrier is sufficient to permit the desired therapeutic effect; and fifthly the therapeutic substance is readily released into saliva upon being chewed.

The present invention has accomplished all these criteria in a novel formulation. According to the invention, a carrier is utilized that has a negative surface charge. The carrier may be formed from natural or synthetic substances, and further may be inherently negatively charged, or may be coated by a reagent that  
 5 imparts the negative charge to the surface of the carrier. The carrier should persist in the oral cavity of the animal for a minimum residence time of at least 1 minute. Furthermore, the carrier itself should be palatable for the animal such that the interest of the animal in the carrier is maintained.

The carrier provides a means for introducing the therapeutic agent into the  
 10 oral cavity. The therapeutic substance is located on or near the surface of the chewable object in order for intimate contact between the moisture of saliva and the therapeutic substance to occur almost immediately upon the start of the chewing cycle so as to minimize the possibility that the therapeutic substance will be consumed with the chew, rather than being released in to the oral cavity.

15 An embodiment of the invention describes a formulation that utilizes a proteinaceous animal chew such as rawhide, and a dentally therapeutic cation, (in this example, chlorhexidine) that is maintained on the surface of the chew on the basis of charge attraction. The cationic antimicrobials become strongly bound to negatively-charged surfaces containing negatively charged moieties such as  
 20 carboxylic, phosphate and sulfate moieties by forming salt bridges. Cationic antimicrobials that are released from the carrier in the presence of saliva are observed to have a long duration of action, due to their retention and adherence to the negatively-charged surface in the oral cavity, e.g., enamel hydroxyapatite, acquired pellicle protein, and the oral mucosa.

25 In a preferred embodiment, the cation is rapidly solubilized in the saliva of the oral cavity when the cation is combined with or deposited on the chew in the presence of an alkali metal salt such as sodium gluconate. It has unexpectedly been

found that the presence of the alkali metal salt effectively prevents the cationic compound from precipitating or otherwise adhering to the proteinaceous carrier, thus rendering it readily soluble in saliva during the chewing cycle. The invention is not limited to a solubilization process that utilizes an alkali metal salt. Alternative  
5 secondary agents are contemplated that provide a means to readily release cations into saliva. Thus, the therapeutic cation is released into the salivary solution during the chewing cycle, rather than carried into the intestinal tract as a result of being bound irreversibly to the carrier.

Cationic antimicrobials contemplated to have utility in the invention include  
10 chlorhexidine diacetate, chlorhexidine digluconate, cetylpyridinium chloride, domiphen bromide, benzalkonium chloride, benzethonium chloride, and alexidene.

Alkali metal salts having utility in the invention include sodium and potassium salts of hydrochloric acid, hydrobromic acid, gluconic acid, and acetic acid.

15 Auxiliary ingredients such as flavorants and film-forming agents may be included in the compositions to provide a specific palatability or coating effect respectively. In particular, film formers such as hydroxypropylcellulose, carrageenan and polyvinylpyrrolidone may provide for a more uniform coating of the carrier surface with the inventive compositions. The auxiliary ingredients are  
20 not essential for the practice of the invention.

An example of the inventive composition is prepared as follows:

### EXAMPLES

EXAMPLE 1: Preparation of a rawhide chew having antimicrobial activity.

25

5 lbs of dried rectangular rawhide chews were basted with the following solution using a spray bottle:

Chlorhexidine digluconate	24 grams
sodium gluconate	24 grams
deionized water	952 grams

5

The chews were coated at a rate of approximately 114 grams of basting solution per 5 lbs of rawhide. The resulting wet basted chews were dried at 40°C for 24 hours and subsequently placed in airtight bags.

10

EXAMPLE 2: Assay demonstrating rapid solubilization of the therapeutic composition.

Rawhide chews (10 grams cut into squares of approximately 1/4" on each side) containing the therapeutic composition (e.g., chlorhexidine) were placed in distilled water (20 mls) shaken for 60 seconds, and the resulting filtrate assayed for the presence of chlorhexidine in solution by infrared spectroscopy. Over 80% (0.486 mg/ml) of the theoretical soluble chlorhexidine (0.6mg/ml) was found in solution. A rawhide chew basted with a solution containing chlorhexidine digluconate but without sodium gluconate showed a soluble chlorhexidine level of only 0.03mg/ml.

EXAMPLE 3: Use of different carriers for delivery of a therapeutic agent

Using the assay in Example 2, the therapeutic composition is shown to be effective when administered with a proteinaceous carrier such as a rawhide chew or a food stuff, and furthermore the food stuff may be composed either wholly or partly of protein.